Commentary
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib

https://doi.org/10.1016/j.clml.2020.06.014Get rights and content

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.

Keywords

Allogeneic stem cell transplantation
COVID-19
Graft-versus-host disease
Immunocompromised
JAK inhibitor

Cited by (0)

View Abstract